Lasa Supergenerics Intrinsic Value
Lasa Supergenerics (LASA) median intrinsic value is ₹3.71 from 3 valuation models (range ₹3–₹17), vs current price ₹6.69 — -44.5% downside (Trading Above Calculated Value), margin of safety -80.3%. For current market price and key ratios, visit Lasa Supergenerics share price today.
LASA Valuation Methods Summary — DCF, Graham Number & P/E
Lasa Supergenerics intrinsic value across 3 models vs current price ₹6.69 — upside/downside and value range per method. See LASA P/B ratio history to compare market price against book value per share.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹16.73 | ₹15.06 - ₹18.40 | +150.1% | Book Value/Share: ₹16.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2.80 | ₹2.52 - ₹3.08 | -58.1% | Revenue/Share: ₹1.40, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹3.71 | ₹2.97 - ₹4.45 | -44.5% | CF Growth: 5.0%, Discount: 15% |
LASA Intrinsic Value vs Market Price — All Valuation Models
Lasa Supergenerics fair value range ₹3–₹17 vs current market price ₹6.69 across 3 valuation models. Check LASA market cap trends to track the company's total market size over time.
LASA Intrinsic Value Analysis — Undervalued or Overvalued?
Lasa Supergenerics median intrinsic value ₹3.71, current price ₹6.69 — Trading Above Calculated Value by 44.5%, margin of safety -80.3%.
What is the intrinsic value of LASA?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Lasa Supergenerics (LASA) is ₹3.71 (median value). With the current market price of ₹6.69, this represents a -44.5% variance from our estimated fair value.
The valuation range spans from ₹2.80 to ₹16.73, indicating ₹2.80 - ₹16.73.
Is LASA undervalued or overvalued?
Based on our multi-method analysis, Lasa Supergenerics (LASA) appears to be trading above calculated value by approximately 44.5%.
LASA Financial Health — Key Ratios vs Industry Benchmarks
Lasa Supergenerics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 33.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -20.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 417.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.07x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
LASA Cash Flow Quality — Operating & Free Cash Flow
Lasa Supergenerics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-17 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹9 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹41 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |